Medtronic's bone graft linked to surgery complications, FDA warns

09/4/2008 | Wall Street Journal, The

The FDA has received multiple reports during a four-year period of serious problems stemming from the off-label use of Medtronic's Infuse Bone Graft, a biologically engineered liquid used in spine-repair surgeries to aid bone growth. Medtronic said it has informed doctors about the product's possible side effects and emphasized that the complication rate is low.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care